Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Jaguar Health (JAGX) Return on Sales (2016 - 2025)

Jaguar Health (JAGX) has disclosed Return on Sales for 11 consecutive years, with 2.35% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Sales fell 7.0% to 2.35% in Q3 2025 year-over-year; TTM through Sep 2025 was 2.62%, a 190.0% increase, with the full-year FY2024 number at 3.36%, up 93.0% from a year prior.
  • Return on Sales was 2.35% for Q3 2025 at Jaguar Health, up from 2.68% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 1.43% in Q4 2024 to a low of 2346.83% in Q2 2021.
  • A 5-year average of 152.09% and a median of 4.05% in 2023 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: tumbled -234392bps in 2021, then soared 234362bps in 2022.
  • Jaguar Health's Return on Sales stood at 6.88% in 2021, then skyrocketed by 64bps to 2.51% in 2022, then tumbled by -61bps to 4.05% in 2023, then soared by 65bps to 1.43% in 2024, then plummeted by -64bps to 2.35% in 2025.
  • Per Business Quant, the three most recent readings for JAGX's Return on Sales are 2.35% (Q3 2025), 2.68% (Q2 2025), and 4.79% (Q1 2025).